Dr. Reddy's Laboratories announces the launch of Venlafaxine ER Tablets in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") has announced the launch of Venlafaxine ER Tablets which is therapeutically equivalent to Venlafaxine Extended-Release Tablets, 150 mg and 225 mg, of Osmotica Pharmaceutical US LLC approved by the U.S. Food and Drug Administration (USFDA).

The brand and generic had U.S. sales of approximately $51 million MAT for the most recent twelve months ending in October 2021 according to IQVIA Health*.

Dr. Reddy's Venlafaxine ER Tablets are available in 150 mg and 225 mg strengths in bottle count sizes of 30 and 90.

Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 4600.75 as compared to the previous close of Rs. 4571.20. The total number of shares traded during the day was 10893 in over 1844 trades.

The stock hit an intraday high of Rs. 4617.60 and intraday low of 4566.80. The net turnover during the day was Rs. 49988084.00.

Source : Equity Bulls

Keywords

DrReddysLaboratories INE089A01023 RDY Pharmaceuticals VenlafaxineERTablets OsmoticaPharmaceuticalUSLLC USFDA